Moderna Brass Hit With Investor Suit Over RSV Shot Claims
By Emilie Ruscoe · October 28, 2024, 8:37 PM EDT
Officers and directors of Moderna face shareholder derivative allegations that they overstated how effective the company's RSV vaccine candidate was as the pharmaceutical giant sought regulatory permission to expedite its development....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login